Novo Nordisk’s Bold Gambit to Reclaim US Market Dominance

Novo Nordisk DK0062498333

Facing intense competitive pressure, Danish pharmaceutical leader Novo Nordisk is executing a dramatic strategic pivot. With its shares down more than 51% since the start of the year, management is deploying aggressive tactics to defend its crucial US market position against rival Eli Lilly. The company’s latest moves signal a fundamental shift from premium pricing to volume-driven market share defense.

In a significant departure from conventional distribution models, Novo Nordisk will begin selling its blockbuster weight-loss medication Wegovy directly to employers starting January 1. This strategic maneuver effectively circumvents the powerful intermediary Pharmacy Benefit Managers (PBMs) that typically control drug distribution in the United States.